Huuuummmm,,is it possible that these companies having discussions with RVX are not interested in the same indications. So a Pharma that might be into CKD is wanting to aquire that point when it is clear several other end points are also being incorporated into the one trial, BoM2. It may be very complicated because of the many positive attributes of apabetalone. DMcC can possibly see more $$$ coming into the fold by splitting these indications up between Phamas while Pharma is not receptive to it..yet anyway...Just thinking here. Maybe BP will bite the bullet before year end and make a substantial offer for all,,,,,DMcC included,,,,,,like Secretariat,,and Don can go out to pasture as wealthy stud,,,,,!